# A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

> **NCT05493631** · PHASE1 · COMPLETED · sponsor: **GC Biopharma Corp** · enrollment: 15 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **BIOLOGICAL:** MG1113

## Key facts

- **NCT ID:** NCT05493631
- **Lead sponsor:** GC Biopharma Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-24
- **Primary completion:** 2024-12-11
- **Final completion:** 2024-12-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05493631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05493631, "A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05493631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*